Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 21455987)

1.

Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.

Kogias E, Osterberg N, Baumer B, Psarras N, Koentges C, Papazoglou A, Saavedra JE, Keefer LK, Weyerbrock A.

Int J Cancer. 2012 Mar 1;130(5):1184-94. doi: 10.1002/ijc.26106. Epub 2011 Jul 21.

2.

Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.

Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock A.

Nitric Oxide. 2013 Apr 1;30:17-25. doi: 10.1016/j.niox.2013.01.003. Epub 2013 Jan 28.

3.

JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.

Weyerbrock A, Osterberg N, Psarras N, Baumer B, Kogias E, Werres A, Bette S, Saavedra JE, Keefer LK, Papazoglou A.

Neurosurgery. 2012 Feb;70(2):497-510; discussion 510. doi: 10.1227/NEU.0b013e31823209cf.

4.

A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins.

Townsend DM, Findlay VJ, Fazilev F, Ogle M, Fraser J, Saavedra JE, Ji X, Keefer LK, Tew KD.

Mol Pharmacol. 2006 Feb;69(2):501-8. Epub 2005 Nov 15.

5.

Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.

Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD.

Mol Pharmacol. 2004 May;65(5):1070-9.

6.

Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro.

Weyerbrock A, Baumer B, Papazoglou A.

J Neurosurg. 2009 Jan;110(1):128-36. doi: 10.3171/2008.6.17607.

PMID:
18991497
7.

Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.

Grossman R, Brastianos H, Blakeley JO, Mangraviti A, Lal B, Zadnik P, Hwang L, Wicks RT, Goodwin RC, Brem H, Tyler B.

J Neurooncol. 2014 Jan;116(1):59-65. doi: 10.1007/s11060-013-1268-2. Epub 2013 Nov 2.

8.

Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Kumar V, Hong SY, Maciag AE, Saavedra JE, Adamson DH, Prud'homme RK, Keefer LK, Chakrapani H.

Mol Pharm. 2010 Feb 1;7(1):291-8. doi: 10.1021/mp900245h.

9.

The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.

Grossman R, Rudek MA, Brastianos H, Zadnik P, Brem H, Tyler B, Blakeley JO.

Cancer Chemother Pharmacol. 2012 Jul;70(1):129-39. doi: 10.1007/s00280-012-1867-1. Epub 2012 May 27.

10.

Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.

Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2079-84. doi: 10.1007/s00432-012-1290-3. Epub 2012 Jul 24.

PMID:
22825126
11.

Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.

Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.

Cancer Chemother Pharmacol. 2013 Jul;72(1):93-100. doi: 10.1007/s00280-013-2172-3. Epub 2013 May 7.

PMID:
23649683
12.

Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas.

Weyerbrock A, Walbridge S, Pluta RM, Saavedra JE, Keefer LK, Oldfield EH.

J Neurosurg. 2003 Oct;99(4):728-37.

PMID:
14567609
13.
14.

Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.

Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, Shih CM.

Free Radic Biol Med. 2012 Jan 15;52(2):377-91. doi: 10.1016/j.freeradbiomed.2011.10.487. Epub 2011 Nov 3.

PMID:
22094224
15.

Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.

Chakrapani H, Wilde TC, Citro ML, Goodblatt MM, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2008 Mar 1;16(5):2657-64. Epub 2007 Nov 17.

16.

Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.

Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, Brem H.

Neurosurgery. 2010 Mar;66(3):530-7; discussion 537. doi: 10.1227/01.NEU.0000365263.14725.39.

PMID:
20173548
17.

Modulation of KCa channels increases anticancer drug delivery to brain tumors and prolongs survival in xenograft model.

Ningaraj NS, Sankpal UT, Khaitan D, Meister EA, Vats TS.

Cancer Biol Ther. 2009 Oct;8(20):1924-33. Epub 2009 Oct 12.

PMID:
19738431
18.
19.

Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO.

Hutchens S, Manevich Y, He L, Tew KD, Townsend DM.

Invest New Drugs. 2011 Oct;29(5):719-29. doi: 10.1007/s10637-010-9407-5. Epub 2010 Mar 16.

20.

Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.

Rainov NG, Fels C, Droege JW, Schäfer C, Kramm CM, Chou TC.

Cancer Gene Ther. 2001 Sep;8(9):662-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk